Insider Transactions in Q1 2024 at Biogen Inc. (BIIB)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
262
-5.09%
|
$57,902
$221.23 P/Share
|
|
Feb 16
2024
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-2.32%
|
$533,703
$219.08 P/Share
|
|
Feb 16
2024
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,037
+4.55%
|
-
|
|
Feb 16
2024
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,264
-7.9%
|
$495,816
$219.08 P/Share
|
|
Feb 16
2024
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
4,704
+13.88%
|
-
|
|
Feb 16
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,438
-8.33%
|
$752,922
$219.08 P/Share
|
|
Feb 16
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,720
+13.79%
|
-
|
|
Feb 16
2024
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
396
-3.17%
|
$86,724
$219.08 P/Share
|
|
Feb 16
2024
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,345
+9.61%
|
-
|
|
Feb 16
2024
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
952
-4.76%
|
$208,488
$219.08 P/Share
|
|
Feb 16
2024
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,017
+9.06%
|
-
|
|
Feb 16
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
108
-2.05%
|
$23,868
$221.49 P/Share
|
|
Feb 16
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-4.36%
|
$102,492
$219.08 P/Share
|
|
Feb 16
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,208
+10.0%
|
-
|
|
Feb 16
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
610
-3.17%
|
$133,590
$219.08 P/Share
|
|
Feb 16
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,260
+6.1%
|
-
|
|
Feb 15
2024
|
Eric K Rowinsky Director |
BUY
Open market or private purchase
|
Direct |
455
+2.16%
|
$101,010
$222.54 P/Share
|
|
Feb 12
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
419
-8.49%
|
$100,141
$239.45 P/Share
|
|
Feb 09
2024
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
634
-5.38%
|
$152,160
$240.98 P/Share
|
|
Feb 09
2024
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,158
+15.49%
|
-
|
|
Feb 09
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-7.04%
|
$89,760
$240.98 P/Share
|
|
Feb 09
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,212
+18.59%
|
-
|
|
Feb 09
2024
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
445
-4.9%
|
$106,800
$240.98 P/Share
|
|
Feb 09
2024
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,515
+14.3%
|
-
|
|
Feb 09
2024
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
245
-4.44%
|
$58,800
$240.98 P/Share
|
|
Feb 09
2024
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
833
+13.11%
|
-
|
|
Feb 09
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,431
-8.15%
|
$343,440
$240.98 P/Share
|
|
Feb 09
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,257
+15.65%
|
-
|
|
Feb 09
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
761
-7.99%
|
$182,640
$240.98 P/Share
|
|
Feb 09
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,272
+19.25%
|
-
|
|
Feb 09
2024
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
938
-1.88%
|
$225,120
$240.98 P/Share
|
|
Feb 09
2024
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,575
+4.9%
|
-
|
|
Feb 08
2024
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
498
-4.92%
|
$119,520
$240.3 P/Share
|
|
Feb 08
2024
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,635
+13.91%
|
-
|
|
Feb 08
2024
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
655
-1.36%
|
$157,200
$240.3 P/Share
|
|
Feb 08
2024
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,190
+4.35%
|
-
|
|
Feb 08
2024
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
621
-7.59%
|
$149,040
$240.3 P/Share
|
|
Feb 08
2024
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,043
+19.97%
|
-
|
|
Feb 08
2024
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
253
-5.12%
|
$60,720
$240.3 P/Share
|
|
Feb 08
2024
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
788
+13.75%
|
-
|
|
Feb 08
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
638
-8.08%
|
$153,120
$240.3 P/Share
|
|
Feb 08
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,101
+21.02%
|
-
|
|
Feb 08
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-5.08%
|
$183,600
$240.3 P/Share
|
|
Feb 08
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,335
+13.42%
|
-
|
|
Feb 02
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
634
-13.4%
|
$155,330
$245.93 P/Share
|
|
Feb 01
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
561
-10.6%
|
$138,567
$247.83 P/Share
|
|
Feb 01
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,828
+25.67%
|
-
|